Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Jan Grimm
|
| gptkbp:collaboratedWith |
gptkb:Biogen
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:developedBy |
gptkb:aducanumab
|
| gptkbp:focusesOn |
neurodegenerative diseases
antibody therapeutics |
| gptkbp:foundedIn |
2006
|
| gptkbp:headquartersLocation |
gptkb:Zurich
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neurimmune
|
| gptkbp:notableFor |
collaboration with Biogen
|
| gptkbp:productPipelineIncludes |
therapies for Parkinson's disease
therapies for ALS therapies for Alzheimer's disease |
| gptkbp:specializesIn |
human-derived monoclonal antibodies
|
| gptkbp:website |
https://www.neurimmune.com/
|
| gptkbp:bfsParent |
gptkb:Sol_J._Barer
gptkb:aducanumab |
| gptkbp:bfsLayer |
7
|